TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23977257

Group type: EXPERIMENTAL
Intervention: Multifocal perinatal home-visiting intervention using psychologists
Number of subjects: 440

Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 440
Study: 21744191

Group type: EXPERIMENTAL
Intervention: Clinical pharmacy services, intensive follow-up by a clinical pharmacist for 6 months.
Number of subjects: 152

Group type: COMPARATOR
Intervention: Standard medical care provided to control group patients for 6 months.
Number of subjects: 152
Study: 19337777

Group type: EXPERIMENTAL
Intervention: Water spray
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sitz bath
Number of subjects: 120
Study: 16778714

Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg after pretreatment with clarithromycin 800 mg/d
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg after pretreatment with fluvoxamine 50 mg/d
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg after pretreatment with placebo
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 15306269

Group type: EXPERIMENTAL
Intervention: Male condom
Number of subjects: 108

Group type: COMPARATOR
Intervention: Female condom
Number of subjects: 108
Study: 11781651

Group type: COMPARATOR
Intervention: IL‐10
Number of subjects: 0

Group type: COMPARATOR
Intervention: TNF‐alpha
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL‐6
Number of subjects: 0
Study: 9668740

Group type: EXPERIMENTAL
Intervention: One-to-one midwifery (study group)
Number of subjects: 1403

Group type: COMPARATOR
Intervention: Conventional care (control group)
Number of subjects: 1403
Study: 7817152

Group type: EXPERIMENTAL
Intervention: Midazolam (0.3 mg/kg body weight)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Midazolam (0.3 mg/kg body weight) plus Ketamine (1.0 mg/kg body weight)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Midazolam plus Ketamine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Midazolam and Midazolam plus Ketamine
Number of subjects: 24
Study: 3379143

Group type: EXPERIMENTAL
Intervention: Haloperidol (0.5 mg intramuscularly or 1.0 mg orally)
Number of subjects: 34
Study: 31323050

Group type: EXPERIMENTAL
Intervention: Mindfulness Training (MT) - 4 sessions of 20 minutes each
Number of subjects: 66

Group type: COMPARATOR
Intervention: Book Learning Control
Number of subjects: 66
Study: 28569123

Group type: EXPERIMENTAL
Intervention: Mechanical embolectomy with the Trevo device
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard medical therapy alone
Number of subjects: 500
Study: 26554316

Group type: EXPERIMENTAL
Intervention: Integrated treatment in a specialized open hospital ward with disorder-specific group therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Treatment as usual in an open general psychiatric ward
Number of subjects: 100
Study: 22983284

Group type: EXPERIMENTAL
Intervention: Glycyrrhizin (75 mg three times daily for 6 days)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (for 6 days)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Glycyrrhizin
Number of subjects: 14
Study: 21733061

Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg qd)
Number of subjects: 515

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 515
Study: 19705923

Group type: EXPERIMENTAL
Intervention: tesofensine (0.3, 0.6, 0.9, 1.2 mg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: meloxicam 30 mg
Number of subjects: 33

Group type: COMPARATOR
Intervention: meloxicam 30 mg with cholestyramine
Number of subjects: 33
Study: 16813885

Group type: EXPERIMENTAL
Intervention: Combined orchiectomy and radiotherapy
Number of subjects: 91

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 91
Study: 15052778

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 54

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 54
Study: 12544371

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 68

Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 68
Study: 10884288

Group type: EXPERIMENTAL
Intervention: Cultured skin fibroblasts from SLS patients
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Plasma concentrations in SLS patients
Number of subjects: 11

Group type: COMPARATOR
Intervention: Cultured skin fibroblasts from normal controls
Number of subjects: 11
Study: 8771595

Group type: EXPERIMENTAL
Intervention: triazolam (0.25 mg)
Number of subjects: 67

Group type: COMPARATOR
Intervention: loprazolam (1 mg)
Number of subjects: 67
Study: 1607582

Group type: EXPERIMENTAL
Intervention: Encainide, flecainide or moricizine (upwardly titrated doses)
Number of subjects: 2371

Group type: EXPERIMENTAL
Intervention: Study drugs (encainide, flecainide or moricizine)
Number of subjects: 2371
Study: 4042746

Group type: EXPERIMENTAL
Intervention: Postcircumcision blood sampling at 30 min
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Postcircumcision blood sampling at 90 min
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Postcircumcision blood sampling at 120 min
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Postcircumcision blood sampling at 240 min
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Additional group of 10 newborns
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Behavioral state observation during circumcision
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Quiet sleep observation
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Postcircumcision observation of quiet sleep
Number of subjects: 80
Study: 3305114

Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 30394918

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 38

Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 38
Study: 28452657

Group type: EXPERIMENTAL
Intervention: Ventriculosubgaleal shunts (VSGS)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Ventricular reservoirs (VR)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: VSGS
Number of subjects: 145

Group type: COMPARATOR
Intervention: VR
Number of subjects: 145
Study: 26182069

Group type: EXPERIMENTAL
Intervention: CBT-PPT SB
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: General SB
Number of subjects: 283

Group type: COMPARATOR
Intervention: Waiting List Control (WL)
Number of subjects: 283
Study: 23837826

Group type: EXPERIMENTAL
Intervention: Exercise programme (30-min moderate-to-vigorous exercise)
Number of subjects: 56
Study: 21641362

Group type: EXPERIMENTAL
Intervention: Adiponectin greater than the median (4,477 ng/mL)
Number of subjects: 3931
Study: 19489234

Group type: EXPERIMENTAL
Intervention: Anterolateral approach (< or = 10 cm incision)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard posterolateral approach
Number of subjects: 110
Study: 16774900

Group type: EXPERIMENTAL
Intervention: Mediterranean Lifestyle Program (MLP)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 279
Study: 15377172

Group type: EXPERIMENTAL
Intervention: LJP 1082 (B-cell toleragen)
Number of subjects: 0
Study: 11224578

Group type: EXPERIMENTAL
Intervention: High fluoride ingestion (2.4, 4.6, 5.6, and 13.5 mg/l)
Number of subjects: 200
Study: 9143000

Group type: EXPERIMENTAL
Intervention: Corticotropin-releasing hormone (CRH) 10 micrograms
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Adrenocorticotropic hormone (ACTH) 1 microgram
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Corticotropin-releasing hormone (CRH)
Number of subjects: 10
Study: 8204806

Group type: EXPERIMENTAL
Intervention: Heparinase-modified TEG assay
Number of subjects: 51
Study: 2976000

Group type: EXPERIMENTAL
Intervention: Acitretin-PUVA
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Etretinate-PUVA
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo-PUVA
Number of subjects: 65
Study: 30664514

Group type: EXPERIMENTAL
Intervention: Mid-thoracic spine mobilization
Number of subjects: 33

Group type: COMPARATOR
Intervention: Therapeutic exercise (foam roller exercises)
Number of subjects: 33
Study: 29183529

Group type: EXPERIMENTAL
Intervention: One-step procedure of laparoscopic cholecystectomy (LC) with endoscopic retrograde cholangiopancreatography (ERCP) + endoscopic sphincterotomy (EST)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Two-step procedure of laparoscopic cholecystectomy (LC) with ERCP + EST
Number of subjects: 63
Study: 25416723

Group type: EXPERIMENTAL
Intervention: Ipilimumab (10 mg/kg in 11/15 patients)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High-dose glucocorticoids (n=11) or physiological replacement doses (n=4)
Number of subjects: 15
Study: 23311604

Group type: EXPERIMENTAL
Intervention: Coca-Cola without resin infiltration
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Coca-Cola with resin infiltration
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sprite without resin infiltration
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sprite with resin infiltration
Number of subjects: 30
Study: 21597235

Group type: EXPERIMENTAL
Intervention: Voluntary waiting at home on full pay if the family became Influenza like Illness (ILI) (Cohort 1)
Number of subjects: 15314

Group type: COMPARATOR
Intervention: Not waiting at home (Cohort 2)
Number of subjects: 15314

Group type: EXPERIMENTAL
Intervention: Workers asked to wait at home (Cohort 1)
Number of subjects: 15314

Group type: COMPARATOR
Intervention: Workers whose family got ILI but were not asked to wait (Cohort 2)
Number of subjects: 15314
Study: 18467909

Group type: EXPERIMENTAL
Intervention: Lactulose (30-60 ml/day)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Probiotics (1 capsule three times/day containing Streptococcus faecalis 60 million, Clostridium butyricum 4 million, Bacillus mesentricus 2 million, lactic acid bacillus 100 million)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Lactulose plus probiotics
Number of subjects: 190
Study: 16856904

Group type: EXPERIMENTAL
Intervention: Metronidazole plus amoxicillin (M+A) for 7 days
Number of subjects: 22

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) and two placebos
Number of subjects: 22
Study: 14531210

Group type: EXPERIMENTAL
Intervention: Bosentan (Tracleer‐Actelion)
Number of subjects: 0
Study: 11753266

Group type: EXPERIMENTAL
Intervention: CYP3A4 induction (rifampin)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: CYP3A4 inhibition (troleandomycin)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control
Number of subjects: 6
Study: 8981374

Group type: EXPERIMENTAL
Intervention: Reading visually presented words aloud (maximizes perceptual encoding)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Generating words aloud from definitions (maximizes conceptual encoding)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alzheimer's disease patients
Number of subjects: 0
Study: 8493007

Group type: EXPERIMENTAL
Intervention: Peribulbar anesthesia
Number of subjects: 317

Group type: COMPARATOR
Intervention: Retrobulbar anesthesia
Number of subjects: 317

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 317
Study: 3552198

Group type: EXPERIMENTAL
Intervention: Microcomputerized Diagnostic Interview Schedule (DIS)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard problem-oriented non-structured clinical interview (NSI)
Number of subjects: 41
Study: 31485774

Group type: EXPERIMENTAL
Intervention: Higher expression levels of four genes (α‐pinene synthase, GPPS, MC5)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Concentrations of two terpenoid compounds (β‐caryophyllene, α‐humulene)
Number of subjects: 16
Study: 29562041

Group type: EXPERIMENTAL
Intervention: Case management model with individual training on hypertension causes, risk factors, significance, unwanted side effects, medication treatment, and lifestyle changes.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention offered).
Number of subjects: 0
Study: 26105535

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Physical Fitness Exercise Program
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 57
Study: 24044709

Group type: EXPERIMENTAL
Intervention: 810-nm subthreshold diode micropulse (SDM) laser treatment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 15
Study: 21087166

Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (50-μg) plus oxytocin
Number of subjects: 101

Group type: COMPARATOR
Intervention: Oxytocin alone
Number of subjects: 101
Study: 19293667

Group type: EXPERIMENTAL
Intervention: On-pump surgery
Number of subjects: 92

Group type: COMPARATOR
Intervention: Off-pump surgery
Number of subjects: 92
Study: 17108825

Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 14728932

Group type: EXPERIMENTAL
Intervention: Different chemotherapy regimens
Number of subjects: 9683

Group type: EXPERIMENTAL
Intervention: EORTC QLQ-C30
Number of subjects: 9683
Study: 11514368

Group type: EXPERIMENTAL
Intervention: Intracoronary gamma-irradiation (15 Gy at 2 mm from the source)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: High-dose gamma-irradiation (18 Gy at 2 mm from the source)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo (Long WRIST)
Number of subjects: 89
Study: 9024023

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg IV administered at the end of surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg IV administered before induction of anesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (saline 5 mL) administered prior to induction and at the end of surgery
Number of subjects: 0
Study: 8440855

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention strategy including moderate intensity endurance-building exercise (walking), strength and balance training, home safety improvements, and mental practice
Number of subjects: 1323

Group type: COMPARATOR
Intervention: Usual care from the HMO
Number of subjects: 1323
Study: 3325331

Group type: EXPERIMENTAL
Intervention: 2 X 2.5 mg dihydroergotamine (DETMS retard) daily (n = 10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo tablets (n = 10)
Number of subjects: 30
Study: 29544871

Group type: EXPERIMENTAL
Intervention: Transcatheter PFO closure
Number of subjects: 120

Group type: COMPARATOR
Intervention: Medication-only group (Control)
Number of subjects: 120
Study: 26452718

Group type: EXPERIMENTAL
Intervention: Resource facilitation services for 15 months
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study: 25376140

Group type: EXPERIMENTAL
Intervention: Arthrocentesis (AC) with corticosteroids (dexamethasone 8 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Arthrocentesis (AC) without corticosteroids
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (AC with and without corticosteroids)
Number of subjects: 60
Study: 22579678

Group type: EXPERIMENTAL
Intervention: CAB sequence
Number of subjects: 340

Group type: COMPARATOR
Intervention: ABC sequence
Number of subjects: 340
Study: 20122374

Group type: EXPERIMENTAL
Intervention: Videoteleconferencing anger management therapy (n = 61)
Number of subjects: 125

Group type: COMPARATOR
Intervention: In-person anger management therapy (n = 64)
Number of subjects: 125
Study: 17976228

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 mug/kg IV over 10 min)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 14
Study: 16049200

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Number of subjects: 391

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 391

Group type: COMPARATOR
Intervention: Pravastatin and Placebo
Number of subjects: 391
Study: 12109024

Group type: EXPERIMENTAL
Intervention: Screen-fragmented words presented individually to observers
Number of subjects: 40
Study: 10079448

Group type: EXPERIMENTAL
Intervention: Postoperative glare sensitivity in pseudophakic group
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Preoperative visual acuity and contrast sensitivity correlation
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Preoperative visual acuity and glare difference correlation
Number of subjects: 25

Group type: COMPARATOR
Intervention: Age and visual acuity correlation in control group
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Repeatability of Y-VA examinations
Number of subjects: 25
Study: 7559887

Group type: EXPERIMENTAL
Intervention: GHRH plus atenolol (1 mg/kg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: GHRH plus placebo
Number of subjects: 11
Study: 1617922

Group type: EXPERIMENTAL
Intervention: roxithromycin 300 mg once daily
Number of subjects: 1588

Group type: COMPARATOR
Intervention: roxithromycin 150 mg b.i.d.
Number of subjects: 1588
Study: 6089857

Group type: EXPERIMENTAL
Intervention: edrophonium 1 mg kg‐1
Number of subjects: 23

Group type: COMPARATOR
Intervention: neostigmine 35.7 micrograms kg‐1
Number of subjects: 23
Study: 29952699

Group type: EXPERIMENTAL
Intervention: FAST-FR (high-velocity foam rolling)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: SLOW-FR (slow-velocity foam rolling)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (inactive)
Number of subjects: 17
Study: 28857839

Group type: EXPERIMENTAL
Intervention: Continuous walking (30 min in the morning)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Multiple short bouts of walking (twenty 90-s bouts over 8 h)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (sitting in a chair for 8 h)
Number of subjects: 12
Study: 25363221

Group type: EXPERIMENTAL
Intervention: EBUS-TBNA
Number of subjects: 62

Group type: COMPARATOR
Intervention: TBNA
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: EBUS-TBNA (Group A)
Number of subjects: 62

Group type: COMPARATOR
Intervention: TBNA (Group A)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: EBUS-TBNA (greater than 15 mm)
Number of subjects: 62

Group type: COMPARATOR
Intervention: TBNA (greater than 15 mm)
Number of subjects: 62
Study: 22773670

Group type: COMPARATOR
Intervention: Enamel prophylaxis (Control)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Etched with 35% phosphoric acid for 15 seconds (Group II)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Etched with 35% phosphoric acid for 60 seconds (Group III)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Conditioned with Prompt L‐pop self‐etching primer (Group IV)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Conditioned with Xeno III self‐etching primer (Group V)
Number of subjects: 50
Study: 19389083

Group type: EXPERIMENTAL
Intervention: Imidafenacin (0.1 mg twice daily)
Number of subjects: 781

Group type: COMPARATOR
Intervention: Propiverine (20 mg once daily)
Number of subjects: 781

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 781
Study: 17617116

Group type: EXPERIMENTAL
Intervention: Covered stent (Group 1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Uncovered prosthesis (Group 2)
Number of subjects: 80
Study: 14754977

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 100 microg twice daily via metered-dose inhaler and Babyhaler spacer device
Number of subjects: 625

Group type: COMPARATOR
Intervention: Sodium cromoglycate (SCG) 5 mg 4 times daily via metered-dose inhaler and Nebuhaler spacer device
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 625

Group type: COMPARATOR
Intervention: Sodium cromoglycate (SCG)
Number of subjects: 625
Study: 11165331

Group type: EXPERIMENTAL
Intervention: Head orientation cue (tilting head towards right or left shoulder based on gain)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Target orientation cue (rotating home and target positions based on gain)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arm posture cue (changing elbow angle from full flexion to full extension based on gain)
Number of subjects: 0
Study: 9924241

Group type: EXPERIMENTAL
Intervention: remifentanil 1 microgram kg‐1
Number of subjects: 30

Group type: COMPARATOR
Intervention: saline (control group)
Number of subjects: 30
Study: 8154289

Group type: EXPERIMENTAL
Intervention: Phase 1 (2‐3 days after injury)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Phase II (4‐17 days after injury)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Phase III (4‐45 days after injury)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (cadaver knees)
Number of subjects: 55
Study: 3278955

Group type: EXPERIMENTAL
Intervention: Omeprazole 30 mg daily
Number of subjects: 176

Group type: COMPARATOR
Intervention: Cimetidine 1 g daily
Number of subjects: 176
Study: 29492863

Group type: EXPERIMENTAL
Intervention: HPβCD-diclofenac
Number of subjects: 1289

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1289
Study: 27556830

Group type: EXPERIMENTAL
Intervention: Team-based care for CHD
Number of subjects: 5
Study: 25708452

Group type: EXPERIMENTAL
Intervention: MTX + prednisone
Number of subjects: 0

Group type: COMPARATOR
Intervention: MTX + placebo
Number of subjects: 0
Study: 23015537

Group type: EXPERIMENTAL
Intervention: Identity Intervention Programme (IIP)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Supportive Psychotherapy (SPI)
Number of subjects: 69
Study: 19861577

Group type: EXPERIMENTAL
Intervention: High baseline CTC (three or more CTC per 7.5 ml of blood)
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: High CTC at baseline
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: High CTC at 1-2 weeks after the start of treatment
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Combined analysis of CTC and CT imaging
Number of subjects: 467
Study: 18594417

Group type: EXPERIMENTAL
Intervention: Enoxaparin administration
Number of subjects: 360

Group type: COMPARATOR
Intervention: High-risk patients (scoring greater than four risk factors)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Body mass index greater than 30 and hormone therapy use
Number of subjects: 360
Study: 16837435

Group type: EXPERIMENTAL
Intervention: Diabetes-specific enteral formulas
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard enteral formulas
Number of subjects: 10
Study: 15017493

Group type: EXPERIMENTAL
Intervention: Venlafaxine 150 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Buspirone 20 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60